Biopharmaceutical company Intarcia Therapeutics has hired Dr. Eddie Li to the newly created position of vice president and global head of regulatory affairs. Li brings more than 20 years of experience in regulatory affairs to Intarcia and will be a member of the executive team overseeing the advancement of ITCA 650 (continuous subcutaneous delivery of exenatide) toward successful registration in key markets around the world. ITCA 650 is the company's diabetes drug candidate currently in global phase III clinical trials for the treatment for type 2 diabetes.
Previously, Li was vice president and head of U.S. regulatory affairs at Novo Nordisk, where he was also a member of the leadership team of the U.S. Clinical, Medical, Regulatory and Safety Organization. Li led and managed all regulatory functions across therapeutic areas including diabetes, obesity, hemophilia and inflammation. Li also worked with Sanofi, where he served in a variety of product/therapeutic team leadership and senior strategic advisory roles within global regulatory affairs. He has held the positions of director and head of regulatory development at Johnson & Johnson/McNeil Consumer & Specialty Pharmaceuticals; senior manager, worldwide regulatory affairs at AstraZeneca; and senior toxicologist at Warner-Lambert/Parke-Davis Pharmaceuticals.